Stem Cell-Based Therapies in Autoimmune Diseases: Current Evidence, Unmet Needs, and Future Directions—A Closing Editorial Review

TL;DR

Stem cell therapies offer a promising alternative to traditional treatments for autoimmune diseases by aiming to restore immune balance rather than just suppress it.

Contribution

This editorial review highlights the distinction between immune reset and immune modulation in stem cell therapies and identifies key challenges and future directions.

Findings

Stem cell therapies, such as hematopoietic stem cell transplantation and mesenchymal stromal cells, show potential for treating autoimmune diseases.

Persistent issues like incomplete immune reconstitution and lack of predictive biomarkers remain significant challenges.

Future directions include standardization, biomarker-driven patient selection, and next-generation techniques like extracellular vesicles.

Abstract

The long-lasting, varied, and complicated nature of immune system issues in autoimmune disorders continues to make treatment difficult. Although standard immunosuppressive and biologic therapies have enhanced disease management, they infrequently provide enduring remission and often result in cumulative damage. Due to this, stem cell treatment has emerged as a potential alternative that aims to restore immunological homeostasis rather than maintain long-term immune suppression. This editorial review provides a comprehensive overview of the current evidence, unmet requirements, and future directions in the field, summarizing the primary contributions of the Special Issue “Stem Cell Therapy for Autoimmune Diseases”. We examine the conceptual distinction between immune reset, as demonstrated by hematopoietic stem cell transplantation, and immune modulation, which is facilitated by mesenchymal stromal cells and their secretome. Systemic sclerosis, neuroimmunological disorders, inflammatory bowel disease, and type 1 diabetes exhibit disease-specific clinical experiences that underscore both context-dependent limitations and therapeutic potential. Meanwhile, an urgent need to address persistent issues such as incomplete immune reconstitution, autoreactive memory cell-driven relapse, a lack of predictive biomarkers, safety concerns, and complex ethical and regulatory problems is addressed. This review concludes by offering perspectives on the future development of this approach, highlighting standardization, biomarker-driven patient selection, and next-generation techniques, including extracellular vesicles and genetically modified cells. This overview marks stem cell therapy as a crucial area of research for the treatment of autoimmune disorders.